Filtered By:
Condition: Heart Attack
Management: Tax
Countries: Australia Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
CONCLUSIONS: Applying a cross-sectorial government perspective budget impact assessment improves our understanding of fiscal changes attributed to ASCVD based on changes in premature mortality and work activity and how this influences lifetime tax contributions and public benefits. The main cost driver observed was associated with reduced ASCVD events that enabled people to remain productive and paying taxes.
PMID: 33464137 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research
